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a  b  s  t  r  a  c  t
Perﬂuorooctanoate  (PFOA)  is a fully  ﬂuorinated  eight-carbon  fatty  acid analog  with  excep-
tional stability  toward  degradation  that  has been used  as an  industrial  surfactant  and
has  been  detected  in environmental  and  biological  matrices.  Exposures  to  PFOA  in the
workplace  and  in  the  environment  have  continuously  stimulated  investigations  into  its
potential  human  health  hazards.  In  this  article,  the results  of  ﬁfteen  unpublished  genotox-
icity  assays  conducted  with  perﬂuorooctanoate  (as  either  the  linear  or linear/branched
ammonium  salt  (APFO)  or the linear/branched  sodium  salt)  are  reported  and  include:
seven  mutation  assays  (three  in  vitro  reverse  mutation  assays  with  histidine  auxotrophic
strains  of  Salmonella  typhimurium,  two  in  vitro  reverse  mutation  assays  with  the trypto-
phan  auxotrophic  Escherichia  coli WP2uvr  strain,  one  in  vitro  mitotic  recombination  (gene
conversion)  assay  with  Saccharomyces  cerevisiae  D4,  and  an  in  vitro  Chinese  hamster  ovary
(CHO)  HGPRT  forward  mutation  assay);  seven  studies  to assess  potential  for  chromosomal
damage  (three  in  vitro  CHO  chromosomal  aberration  studies,  an  in  vitro  human  whole  blood
lymphocyte chromosomal  aberration  study,  and  three  in  vivo  mouse  micronucleus  assays);
and an in vitro  C3H  10T1/2  cell  transformation  assay.  Although  PFOA  has  not  been  demon-
strated  to be  metabolized,  all in  vitro  assays  were  conducted  both  in  the  presence  and  in the
absence of  a  mammalian  hepatic  microsomal  activation  system.  These  assays  were  orig-
inally described  in  twelve  contract  laboratory  reports  which  have  been  available  via the
United  States  Environmental  Protection  Agency  public  docket  (Administrative  Record  226)
for over  a decade;  however,  the  details  of  these  assays  have  not  been  published  previously
in  the  open  scientiﬁc  literature.  With  the  exception  of  limited  positive  ﬁndings  at high
and  cytotoxic  concentrations  in  some  assay  trials  which  reﬂected  the  likely  consequence
of  cytotoxic  disruption  of  normal  cellular  processes  and  not  a speciﬁc  genotoxic  effect,  the
results of the  studies  presented  in this  paper  and other  published  results  clearly  demon-
strate  the absence  of direct  mutagenic  or genotoxic  risk  associated  with PFOA.  This  ﬁnding
is consistent  with  the  physical/chemical  characteristics  of  PFOA  and is  supported  by  other
published  genotoxicity  studies.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
∗ Corresponding author at: 3M Company, 3M Center 220-06-W-08, St.
Paul, MN 55144, USA. Tel.: +1 651 733 9073; fax: +1 651 733 9066.
E-mail  addresses: jlbutenhoff@mmm.com (J.L. Butenhoff),
gerald.kennedy@dupont.com (G.L. Kennedy), rhj.jung@t-online.de
(R.  Jung), s.chang@mmm.com (S.-C. Chang).
http://dx.doi.org/10.1016/j.toxrep.2014.05.012
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. IntroductionPerﬂuorooctanoate (PFOA, CF3(CF2)6CO2−, CASRN 335-
67-1) is a perﬂuorinated carboxylate that has been used
principally in the form of the ammonium salt (NH4+PFOA
or  APFO, CF3(CF2)6CO2NH4, CASRN 3825-26-1) as an
is is an open access article under the CC BY-NC-ND license
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mulsiﬁer in the production of ﬂuoropolymers such
s  polytetraﬂuoroethylene. The carbon-ﬂuorine bonds
mpart extreme stability against degradation of the PFOA
olecule. The stability of PFOA renders it persistent in envi-
onmental and biological matrices. PFOA has been found
idely  distributed in human blood at low part per billion
evels  [1,2] and has been identiﬁed in wildlife and environ-
ental media [3].
The  toxicology of PFOA has been studied extensively
nd detailed review have been published [4–6]. In lab-
ratory toxicology study with mice, exposures to PFOA
eads  to decrease in body weight, triglyceride, and choles-
erol.  The serum elimination half-life is approximately 2–3
eeks  in either male or female mice and the acute oral
D50  is approximately 450 mg/kg. PFOA is tightly bound
o  serum proteins and accumulates in the liver, which
s  the primary target organ for PFOA toxicity. In rodents
uch as mice, the hepatic changes are susceptible, largely
ue  to nuclear xenosensor receptors PPAR activation
hich subsequently leads to hepatocellular hypertrophy
nd proliferation. PFOA can cause developmental delays
nd  neonatal mortalities in mice when pregnant dams are
xposed  to PFOA during gestation; however, most devel-
pmental toxicities appeared to be PPAR-mediated [7]
nd  were not observed when PPAR knockout mice were
valuated.
Even  though the biological properties of PFOA, including
enotoxicity, have been well characterized and reviewed
4–6], the details of many key studies conducted in the
ast  that have examined PFOA for potential genotoxicity
ave not been published. Although the reports for these
tudies have been made public and available through the
SEPA  Administrative Record (Docket AR226), for greater
ccessibility, the experimental details and results of these
ey  studies are summarized and presented herein. Infor-
ation from other published studies is also included in
he  discussion to provide a more complete evaluation of
erﬂuorooctanoate for potential genotoxicity.
. Materials and methods
.1.  Materials
Five perﬂuorooctanoate (PFOA) test materials were
sed in conducting the genotoxicity studies reported
erein. The characteristics of these ﬁve samples and the
peciﬁc  studies in which they were used are summarized
n Table 1. The purity of the solids used in all sam-
les was ≥95%. Four of the PFOA samples were tested as
he  ammonium salt (APFO), and one was tested as the
odium salt (Na+PFOA). Three of the APFO samples and the
a+PFOA sample were produced by electrochemical ﬂuo-
ination  (ECF) and contained approximately 22% branched
somers of PFOA; for example, as representative lot may
ontain  12.6% internal monomethyl (non-alpha); 9% iso-
ropyl;  0.2% tert-butyl; 0.1% gem-dimethyl; and 0.1% alpha
onomethyl. Impurities in ECF-produced PFOA primar-ly  consisted of lesser homologs (C4–C7) at approximately
% with additional minor impurities (monohydro APFO,
onounsaturated APFO, and undeﬁned (possibly) substi-
uted  perﬂuorocyclo species). One of the APFO samples Ta
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was produced by a “telomerization” process, yielding linear
PFOA.  Impurities in the telomer-produced PFOA primarily
were  the C7 and C6 homologs. Four studies were conducted
with  the Na+PFOA as an approximately 20% solution in
water.  Of eight studies conducted with APFO, ﬁve were
tested as solid APFO, and three were tested as the linear
APFO supplied as an approximately 30% solution in water.
In  the instances where Na+PFOA or APFO were supplied
to the testing facilities as solutions in water (30% and 20%
for  Samples D and E, respectively, see Table 1), the aque-
ous  solution was treated as the test material by the testing
facilities without correcting for strength. For ease of com-
parison  between studies, doses or concentrations reported
herein  have been adjusted to reﬂect actual Na+PFOA or
APFO  delivered to the test system in g/mL or g/plate.
All other chemicals used in these tests were reagent-grade.
2.2. Assays to assess potential to cause point mutations
2.2.1. Prokaryotic assay systems
2.2.1.1. S. typhimurium (Sample A, Study 1; Sample D, Study
8;  Sample E, Study 12). Three test materials were used in
three  separate assays to evaluate potential mutagenicity
utilizing S. typhimurium test strains TA98, TA100, TA1535,
TA1537, and TA1538 (Study 1 only), with and without the
presence  of a metabolic activation system. The genotypic
composition of these test strains is detailed in Mortelmans
and Zeiger [8]. The test methods employed were originally
described by Ames et al. [9] and Maron and Ames [10].
Grifﬁth and Long [11] previously provided a brief
description of a study in which S. typhimurium histidine
auxotrophic strains TA98, TA100, TA1535, TA1537, and
TA1538  were used to test APFO for potential mutageni-
city (Sample A, Study 1). A more detailed description of
methods is provided here and study data not shown by
Grifﬁth  and Long are presented in the results. Liver S9
extract was isolated from an adult male Sprague Daw-
ley  rat after AroclorTM 1254 treatment. S9 liver extract
(0.10 mL)  was  mixed with triphosphopyridine nucleotide
(TPN) sodium salt (4 mol), glucose-6-phosphate (5 mol),
sodium  phosphate dibasic (100 mol), MgCl2 (8 mol), and
KCl  (33 mol) prior to each assay. The study was performed
with the test strains both in the presence and absence of S9
activation.  Approximately 108 cells from an overnight cul-
ture  of each indicator strain were added to separate test
tubes  containing 2.0 mL  molten agar supplemented with
biotin  and histidine. APFO concentrations tested ranged
from  0.1 g to 500 g. When microsomal activation was
required, 0.5 mL  of S9 mix  was added. The solution was
gently  mixed and overlaid onto minimal agar plates. After
overlay  had solidiﬁed, the plates were incubated for 48 h
at  37 ◦C for S. typhimurium strains. Vehicle control (50 L
DMSO  per plate) was used as the negative control for all
the  assays while the positive controls used for each strain,
with  or without S9 activation, are listed in Table 2. Plates
were  evaluated both macroscopically and microscopically,
and the number of revertant colonies was counted and
reported. Criteria for a positive response were, in general,
based on data from at least three non-cytotoxic concen-
trations, a positive dose-response, and at least a 2–3 fold Ta
b
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ncrease in revertants per plate as compared to the vehicle
ontrol at the highest dose.
In  two additional assays using APFO (Sample D, Study
)  or Na+PFOA (Sample E, Study 12), S. typhimurium
trains TA98, TA100, TA1535, and TA1537 were used.
he  APFO sample assay was run in duplicate; whereas,
he Na+PFOA sample was tested once. Following dose
ange-ﬁnding studies, doses of 30–1500 g per plate
PFO (Sample D, Study 8) and 20–1000 g per plate of
a+PFOA (Sample E, Study 12) were tested using tripli-
ate  plates at each concentration. Deionized water was
sed  as the negative control, and the positive controls
sed for each strain were as listed in Table 2. When
he S9 metabolic activation system was not incorporated,
liquots of each testing strain (100 L) and test material
50 L) were added to 2.5 mL  of molten selective top agar
aintained at 45 ± 2 ◦C. When S9 activation was required,
.1  mL  AroclorTM 1254-treated male Sprague Dawley
at liver S9 extract homogenates (Molecular Toxicology,
nc., Boone, NC) was mixed with water (0.70 mL), 1 M
aH2PO4/Na2HPO4, pH 7.4 (0.10 mL), 0.25 M glucose-6-
hosphate (0.02 mL), 0.10 M NADP (0.04 mL), and 0.825 M
Cl/0.2  M MgCl2 (0.04 mL). Aliquots of each testing strain
100  L), test material (50 L), and S9 mix  (500 L) were
dded to 2.0 mL  of molten selective top agar maintained at
5  ± 2 ◦C. The mixtures prepared above were vortexed and
verlaid  onto 15 mm × 100 mm agar plates. After overlay
ad solidiﬁed, the plates were inverted and incubated for
2  ± 4 h at 37 ± 2 ◦C. The mean and standard deviation of
he  number of revertant colonies per plate were calculated
rom the individual revertant colony counts from tripli-
ate  cultures at each concentration by strain. Criteria for
 positive response were as described above.
.2.1.2. E. coli reverse mutation assay (Sample D, Study 8;
ample  E, Study 12). The potential mutagenicity of APFO
Study 8) and Na+PFOA (Study 12) was studied in the
.  coli test system using the tryptophan auxotrophic strain
P2uvrA. Methods employed were originally described by
reen  and Muriel [12]. Preparation of cultures, dose ranges,
nd  enumeration of revertant colonies were as described
bove for the S. typhimurium assays conducted as part of
tudies  8 and 12 (Section 2.2.1.1). The positive control for
he  metabolic activation system was 2-aminoanthracene
25 g/plate). When the metabolic activation system was
ot  used, 4-nitroquinoline-N-oxide (1 g/plate) was used
s  the positive control. The mean number of rever-
ant colonies per plate by concentration and strain were
ounted and recorded as described above, and the criteria
or  a positive response were also as described above for the
.  typhimurium test strains (Section 2.2.1.1).
.2.2. Eukaryotic assay systems
.2.2.1. S. cerevisiae mitotic recombination (gene conversion)
ssay (Sample A, Study 1). Also described brieﬂy by Grif-
th  and Long [11] was an assay in which APFO (Sample
)  was tested for potential mutagenicity via non-speciﬁc
NA damage leading to mitotic recombination expressed
s  gene conversion to produce prototrophic revertants in
he  auxotophic heteroallelic D4 strain of S. cerevisiae. The
ssays  followed the S. typhimurium procedures describedports 1 (2014) 252–270 255
above for Study 1 (See 2.2.1.1). Plates were evaluated both
macroscopically and microscopically and the number of
convertant colonies per plate were counted and reported.
Study data not shown by Grifﬁth and Long are presented in
the  results.
2.2.2.2. Chinese hamster ovary/HGPRT forward mutation
assay (Sample C, Study 5). APFO was  also evaluated for
its  potential to induce mutation at HGPRT locus of Chi-
nese  hamster ovary (CHO) cells. CHO cells were grown at
37 ◦C in complete Ham’s F-12 medium (10% fetal bovine
serum (FBS), 1–2 mM l-glutamine, 100 U/mL penicillin, and
100  g/mL streptomycin) and were buffered with 10 mM
HEPES.  Liver S9 homogenates isolated from male Sprague
Dawley rat liver were purchased from Molecular Toxico-
logy,  Inc. (Boone, NC).
Plates  were seeded with cells and incubated at 37 ◦C
for  24 h followed by exposure to positive controls (EMS for
the  non-activated and DMBA for the S9-activated), negative
control  (Ham’s F-12 medium), or APFO (9.75–39 g/mL) for
17  h (non-activated) or 5 h (S9 activated). After exposure,
cells were washed twice with phosphate buffered saline
(PBS)  and incubated for additional 48 h (non-activated)
or 64.5 h (S9 activated) in Ham’s F-12 medium. The cells
were  subsequently harvested, re-plated, and passed every
48–72  h for 6 days for phenotypic expression. Following
this, cells were grown in selective medium speciﬁc for
mutant cells for 9 days allowing for colony formation. The
cells  were rinsed with PBS, ﬁxed in methanol, and stained
with  Giemsa. The results of the assay were evaluated based
on  the number of thioguanine-resistant mutants per 106
surviving cells. The signiﬁcance of the test results were
determined by using the statistical program, Tallarida, R.S.
and  R.B. Murray’s Pharmacological Calculations Procedure,
ANOVA, and Newman–Keuls test for conﬁrmation. The
statistical method determined if there was a signiﬁcant
(p ≤ 0.05) increase in the mutation frequency of the test
article  compared to the negative control article.
2.3. Assays to assess potential for chromosomal damage
2.3.1. Chromosomal aberrations in CHO cells (Sample C,
Study  4; Sample D, Study 7; and Sample E, Study 11)
CHO cells used in this assay were obtained from a
permanent cell line from the University of California San
Francisco. This cell line has an average cycle of 12–14 h with
a  modal chromosomal number of 21. The CHO cells were
grown in McCoy’s 5a culture medium supplemented with
10%  FBS, 1% l-glutamine, 1% penicillin and streptomycin at
approximately 37 ◦C in the atmosphere of 5% CO2.
Three test materials were evaluated in three separate
studies using CHO cells both in the presence and absence of
a  metabolic activation system and with varying test mate-
rial  exposure and harvest times, as summarized in Table 3.
These  were two APFO samples (Sample C, Study 4; Sample
D,  Study 7) and one Na+PFOA sample (Sample E, Study 11).
Positive controls used were mitomycin C (MMC)  for assays
without metabolic activation and cyclophosphamide (CP)
for  assays with metabolic activation. Negative controls
for cultures contained only cells and medium while the
solvent  controls employed the highest concentration of
256
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Table 3
CHO  chromosomal aberrations assay summary (Studies 4, 7, and 11). For aberration evaluation, 100 metaphase cells from each replicate at 4 dose levels were analyzed.
Sample S9 activation Exposure
length  (h)
Harvest
time (h)
Trials Dose range
(g/mL)
Doses
aberrations
evaluated
(g/mL)
Non-cytotoxic  doses Cytotoxic doses Description of
cytotoxicity
Doses
(g/mL)
Increased  % cells
with  aberrations
Doses
(g/mL)
Increased  % cells
with  aberrations
C No 17.6 20 1 12.5–200 75–200 ≤75 No ≥100 No Reduced cell monolayer conﬂuence and
reduced mitotic index.
D No 17.8 20.1 2 18.75–600 30–300  ≤150 No ≥180 No Mitotic index lowered.
D No 3 44.2 1 15–360 30–180 ≤60 No ≥120 No Unhealthy monolayers, reduced mitotic
cells, ∼15% reduction in monolayer
conﬂuence.
E  No 17.6–17.8 20 2 25–400 150–400 <149 No ≥149 No Toxicity ranged from a 95% reduction in
mitotic index at 400 g/mL to a 25–57%
reduction at 150 g/mL; typical at higher
concentrations were unhealthy cell
monolayers, loss of mitotic cells, ﬂoating
dead cells and debris, reduction in cell
layer conﬂuence.
E No 41.8 44.1 1 25–398 50–199 ≤99.6 No ≥149 No Toxicity ranged from a 79% reduction in
mitotic index at 199 g/mL to a 18%
reduction at 149 g/mL; higher
concentrations were lethal.
E  No 3 20 1 50–996 50–498 ≤250 No ≥498 No At 498 (g/mL) a 30% reduction in
conﬂuency was observed. Severe toxicity
at the next dose (748 g/mL). At
748 g/mL, only 38 metaphase cells
were available from the combined
duplicates hence data at this
concentration were excluded; 18% of
cells were observed to have aberrations.
E  No 3 44 1 50–996 100–748 ≤250 No ≥498 Yes At 498 g/mL, there was a 39% reduction
in  conﬂuency. At 748 g/mL, one of the
two  duplicate cultures was observed to
have 11% of cells with aberrations, while
the parallel duplicate had 4% (similar to
the negative and solvent control values).
Cytotoxicity at 748 g/mL: 50% reduction
in  conﬂuency, 57% reduction in mitotic
index, and increased % polyploidal cells
in one of the two duplicate cultures.
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C Yes 2 20 1 125–1500 125–750 ≤500 No ≥750 No Dead monolayers, no mitotic cells,
reduced cell monolayer conﬂuence.
D  Yes 3 20–20.1 2 75–1200 75–750 ≤450 No ≥600 No/Yes A 12.5% increase over control observed in
one  of the two assays at 750 g/mL.
Dose-related reductions in cell
monolayer conﬂuence, with reductions
in mitotic cells at higher concentrations.
At 750, 675, and 600 g/mL, monolayer
conﬂuence was reduced by 45%, 30%, and
15%,  respectively, and mitotic index by
30%, 11%, and 15%, respectively.
D Yes 3 44.2 1 150–900 600–825 ≤600 No ≥675 Yes A 13% increase over control in
aberrations was  observed at 825 g/mL.
Dose-related reductions in cell
monolayer conﬂuence, with reductions
in mitotic cells at higher concentrations.
At 825, 750, and 675 g/mL, monolayer
conﬂuence was reduced 55%, 45%, and
15%, respectively, with mitotic index
reductions of 53%, 56%, and 17%,
respectively.
E  Yes 3 20 2 50–1000 250–1000 ≤500 No ≥750 Yes 14.5–42.7% increases over control in
aberrations at 750 and 1000 g/mL,
respectively. 70–95% reduction in
monolayer conﬂuency at 1000 g/mL
and  14–47% reduction in mitotic index;
slight toxicity noted at 750 g/mL.
E  Yes 3 44.1 1 100–994 100–748 ≤498 No ≥748 No At 994 g/mL, % polyploidy cells
increased and mitotic index reduced by
70%.
Cells increased and mitotic index reduced by 70%.
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solvent used in the test system. All assays were conducted
using duplicate cultures, and data based on the average
of  duplicate cultures was reported. Multiple experimental
trials in the absence and presence of a metabolic activation
system were performed for Samples D and E (Stud-
ies 7 and 11, respectively), while only one trial for each
metabolic activation condition was performed for Sample C
(Study  4).
Assays  conducted in the absence of a metabolic activa-
tion system were performed as follows. In two studies with
APFO,  test concentrations of APFO ranged up to 600 g/mL
and  in the study with Na+PFOA, test concentrations ranged
up  to 996 g/mL. The MMC  positive control concentra-
tions ranged from 0.08 to 1 g/mL. In all cases, cells were
cultured for 24 h prior to treatment by seeding approxi-
mately 0.8–1.2 × 106 cells per 75 cm2 ﬂask into 10 mL  of
McCoy’s 5a culture media followed by incubation with the
test  articles at 37 ◦C for 3–41.8 h (Table 3). Following incu-
bation with test articles, cultures were washed with PBS
and  incubated with fresh medium containing ColcemidTM
(0.1 g/mL) for 2 h, after which the cultures were harvested
from 20 to 44.2 h, based on study (Table 3), and ﬁxed with
absolute methanol:glacial acetic acid (3:1) ﬁxative, dried,
and  stained with 5% Giemsa solution for the analysis of the
mitotic  index and chromosomal aberrations.
Assays conducted in the presence of a metabolic activa-
tion  system were performed as follows. In the two studies
conducted with APFO, tested ranged up to 1500 g/mL
(Sample C, Study 4; and Sample D, Study 7), and, for
Na+PFOA, concentrations tested ranged up to 1000 g/mL
(Sample E, Study 11). Concentrations used for the positive
control agent, CP ranged from 5 to 10 g/mL. Cells were
seeded at approximately 0.8–1.2 × 106 cells per 75 cm2
ﬂask in 10 mL  of McCoy’s 5a culture media and were cul-
tured  for 24 h prior to treatment, after which cells were
incubated for 2–3 h at 37 ◦C in McCoy’s 5a medium with-
out  FBS with added test articles and S9 reaction mixture.
Treated cells then were washed with PBS and fresh medium
and  incubated with ColcemidTM (0.1 g/mL) during the last
2  h of incubation. The metaphase cells were harvested after
20–44.2  h, ﬁxed with absolute methanol:glacial acetic acid
(3:1),  washed, dried, and stained with 5% Giemsa solution
for  the analysis of the mitotic index and chromosomal aber-
ration.
Stained  cells were selected for good morphology, and
only  cells with the number of centromeres equal to the
modal  number of 21 ± 1 were analyzed for mitotic index
and  chromosomal aberrations. A total of 100 cells per dose
level  from each treatment were analyzed for different types
of  chromosomal aberrations. The number of mitotic cells
per  1000 was reported as the mitotic index, and, in evalu-
ation  of chromosomal aberration data, the percent of cells
with  aberration, the percent of cells with more than 1 aber-
ration,  and evidence for increasing amount of damage with
increasing dose was considered, along with evidence of
polyploidy and endoreduplication.
In  these assays, statistical analysis employed the Fisher’s
Exact Test [13] to compare the percentage of cells with
aberrations in each treatment group with the results from
the  solvent controls. A linear trend test of increasing num-
ber  of cells with aberrations with increasing dose [14]eports 1 (2014) 252–270
was  also performed. Signiﬁcance was established when
p  < 0.01.
2.3.2. Chromosomal aberrations in human whole blood
lymphocytes (Sample E, Study 10)
Human venous whole blood from a healthy adult
male donor was  drawn into a heparinized Vacutainer®
tube. Whole blood lymphocyte cultures were obtained
after heparinized blood (0.6 mL)  was incubated with RPMI
1640  culture medium (9.4 mL,  supplemented with 15%
FBS,  100 U/mL penicillin, 100 g/mL streptomycin, 2 mM
l-glutamine, and 1% phytohemagglutinin) at 37 ◦C, and cul-
tures  were incubated for 2 days before treatment with test
compound. Na+PFOA (prepared in water) was evaluated
in  the whole blood lymphocyte culture at concentrations
ranging from 12.4 g/mL to 600 g/mL. Dose levels of
Na+PFOA were selected for the study based on the pre-
liminary range ﬁnder data which evaluated cytotoxicity at
doses  ranging from 0.033 to 1000 g/mL. Fresh RPMI 1640
culture  medium was  used as the negative control for the
assay.  CP (20–50 g/mL in water) and MMC  (0.1–0.3 g/mL
in  water) were used as the positive controls for the assay
in  the presence and absence of S9 metabolic activation,
respectively.
In performing the assay in the absence of a metabolic
activation system, whole blood lymphocyte culture was
initiated  for 2 days followed by exposure to Na+PFOA for
up  to 46 h. The cultures were then washed with PBS fol-
lowed  by incubation with RPMI 1640 medium containing
0.1 g/mL ColcemidTM. Two  hours later, the cells were har-
vested, dried, and stained in 5% Giemsa solution for analysis
of  chromosome aberrations.
When  metabolic activation was  used in the assay
system, a preparation of rat S9 liver extract (15 L, Molec-
ular  Toxicology, Inc., Boone, NC) was mixed with NADP
(1.5  mg/mL) and isocitric acid (2.7 mg/mL). Following 3 h
of  incubation with Na+PFOA or control substances in
the  presence of the S9 activation system, cultures were
washed with PBS, replenished with fresh RPMI 1640 cul-
ture  medium, and incubated for up to 46 h. The cells were
incubated for the rest of the culture period up to the
time of harvest with 0.1 g/mL ColcemidTM present dur-
ing  the last 2 h of incubation. The metaphase cells were
harvested and the resulting cell pellets were re-suspended
with 75 mM KCl hypotonic solution, ﬁxed with absolute
methanol:glacial acetic acid (3:1, v/v), and a portion spread
onto  a microscope slide. After air-drying, the slide was
stained with 5% Giemsa solution and evaluated for mitotic
index  and chromosomal aberrations.
Assessments of chromosomal aberrations and mitotic
indices were performed by ﬁrst selecting cells for appropri-
ate  morphology. Only cells with 46 centromeres (normal
number) were analyzed. A total of 100 cells per dose
level from each treatment were analyzed for different
chromosomal aberrations. Evaluation of cultures was per-
formed  as noted above the assays with CHO cells (Section
2.3.1).
Cochran-Armitage test for linear trend and Fisher’s
Exact Test [15] were employed to compare the per-
centage of cells with aberrations, polyploidy, and
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ndoreduplication. Test article signiﬁcance was  estab-
ished where p < 0.01.
.3.3. In vivo mouse micronucleus assays (Sample C,
tudy  3; Sample D, Study 6; Sample E, Study 9)
Three separate in vivo studies were conducted to assess
he  potential for PFOA to increase micronuclei in poly-
hromatic erythrocytes isolated from mouse bone marrow.
he  methods employed were ﬁrst described by Heddle
t  al. [16]. For all three studies, adult male and female
rl:CD-1® (ICR) BR mice (6–8 weeks old) were purchased
rom Charles River Laboratory (Portage, MI). All mice were
oused  in standard cages; rodent chow (Purina® Certiﬁed
aboratory Pellets® #5002) and tap water were provided
d  libitum. Environmental controls for the animal room
ere  set to maintain a temperature of 72 ± 6 ◦F, humidity
f  55 ± 15%, and a 12-h light/dark cycle. The study facility
as  accredited by the Association for Assessment and for
he  Accreditation of Laboratory Animal Care International.
ll procedures involving mice were reviewed and approved
y  the Institutional Animal Care and Use Committee. Ani-
al  care and procedures followed guidelines as speciﬁed
he  U.S. Department of Health and Human Services Guide
or  the Care and the Use of Laboratory Animals [17].
The  three test articles and dosages utilized were as fol-
ows:
.  Na+PFOA (Sample E, Study 9) dose levels of 250 mg/kg,
500 mg/kg, and 1000 mg/kg were selected based on the
preliminary range ﬁnder data which evaluated the acute
oral toxicity of Na+PFOA which ranged from 100 to
1000 mg/kg. Na+PFOA solutions (prepared in deionized
water) were administered orally as a single dose to
groups of mice (n = 5/sex/dose group/time point). CP
(80 mg/kg) and deionized water were used as positive
and negative controls, respectively.
. APFO (Sample C, Study 3) dose levels of 200 mg/kg,
400 mg/kg, and 800 mg/kg were selected for the study
based on the preliminary range ﬁnder data which eval-
uated the acute oral toxicity of APFO which ranged from
200 to 1000 mg/kg. APFO solutions (prepared in deion-
ized water) were administered orally as a single dose
to primary groups of mice (n = 5/sex/dose group/time
point). A secondary group of mice (n = 5/sex) were also
treated with 800 mg/kg APFO as possible replacements
should mortality occur within the primary group. CP
(80 mg/kg) and deionized water were used as positive
and negative controls, respectively.
. APFO (Sample D, Study 6) was tested in the same man-
ner as for Sample C (Study 3) except that dose levels of
150 mg/kg, 300 mg/kg, and 600 mg/kg were used (based
on the preliminary range ﬁnder data which evaluated
the acute oral toxicity of APFO ranging from 300 to
900 mg/kg), and the secondary group was dosed with
600 mg/kg APFO.
At  designated times (24, 48, and 72 h post dose), mice
reated with APFO or Na+PFOA were euthanized by CO2
sphyxiation, and bone marrow was ﬂushed from the bone
nto  a centrifuge tube containing 3–5 mL  of bovine serum.
ollowing centrifugation and the removal of supernatant,ports 1 (2014) 252–270 259
a  portion of the resulting bone marrow pellet was  spread
onto  a microscope slide, dried, and ﬁxed in methanol
and stained with May-Grunwald and Giemsa. The mice
treated with both the positive and negative control solu-
tions  were euthanized at 24 h post dose only and bone
marrow samples were also harvested and evaluated as
described above. Bone marrow cells were analyzed for
the  presence of micronuclei in both the polychromatic
erythrocyte (PCE), and the mature normochromatic ery-
thocyte  (NCE). Approximately 1000 PCEs per mouse were
scored  and the frequency of micronucleated cells was
expressed as % micronucleated cells based on the number
of  PCEs analyzed. The spontaneous (background) micronu-
clei  frequency was determined based on the number of
PCEs  observed in the optic ﬁelds while scoring the ﬁrst
1000  erythrocytes on the slide. The normal frequency of
micronuclei in this Crl:CD-1 (ICR) BR strain is about 0–0.4%.
The  ratios of PCE to NCE were calculated.
The analysis of data was performed using ANOVA
[18] on either untransformed (when variances are homo-
geneous) or rank transformed (when variances are
heterogeneous) proportions of cells with micronuclei per
animal.  If ANOVA was  signiﬁcant (p < 0.05), a Dunnett’s t-
test  [19,20] was  used to determine which dose groups, if
any,  were signiﬁcantly different from the negative control.
2.4.  Cell transformation assay (Sample B, Study 2)
The potential of PFOA to transform mouse embryo-
derived C3H 10T1/2 cells was studied in vitro based on
methods originally described by Reznikoff et al. [21,22].
Prior to performance of the transformation assay, cytotox-
icity  data were obtained and expressed as plating (cloning)
efﬁciency. APFO (0.1–20 g/mL) was added to the cultures
that were seeded the day before at 300 cells per 60 mm
diameter culture dish. After 24-h exposure (6 replicates
per dose) in 5 mL  Eagle’s basal medium supplemented
with 10% FBS, APFO was removed with a complete change
of  media. Media was replenished every 3 days. After 7
days  in culture, the plates were washed in PBS, ﬁxed with
absolute methanol, and stained with Giemsa. Solvent con-
trol  (10 g/mL DMSO) and serum baseline controls were
included. The number of colonies per plate was  counted
and the plating efﬁciency (PE) was determined by the for-
mula:
PE  = average number of colonies per plate
number of cells seeded per plate
× 100
The study was conducted in two phases in that
colony transformation was evaluated in the ﬁrst phase
while foci transformation was  evaluated in the second
phase. For the colony transformation assay, six replicates
plates seeded with 300 cells per plate were treated with
APFO  (0.1–200 g/mL), a positive control (benzo(a)pyrene,
0.1–10 g/mL), and a solvent control (10 g/mL DMSO) for
24  h. After removal of the chemicals, culture media was
replenished every 3 days. After 14 days, the plates were
washed in PBS, ﬁxed with absolute methanol, and stained
with  Giemsa. Each colony was examined macroscopically
and microscopically and scored for transformation accord-
ing  to criteria of Reznikoff et al. [21].
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For the foci transformation assay, six replicates plates
seeded with 300 cells per plate were treated with APFO
(0.1–100 g/mL), a positive control (butadiene diepox-
ide, 0.0001–0.01 g/mL), and a solvent control (10 g/mL
DMSO). Following exposure for up to 38 days, the plates
were  washed in PBS to remove the chemical, ﬁxed with
absolute methanol, and stained with Giemsa. Focal area
was  examined macroscopically and microscopically and
scored  for transformation according to criteria of Reznikoff
et  al. [21].
3.  Results
3.1. Assays to assess potential to cause point mutations
3.1.1. Prokaryotic assay systems
3.1.1.1. S. typhimurium reverse mutation assays (Sample
A,  Study 1; Sample D, Study 8; Sample E, Study 12).
For these three separate assays, samples tested included
linear APFO (Sample D, tested up to 1500 g/plate), lin-
ear/branched APFO (Sample A, tested up to 500 g/plate),
and linear/branched Na+PFOA (Sample E, tested up to
100  g/plate). No evidence for a signiﬁcant increase in the
number  revertant colonies was obtained in these assays
utilizing several sensitive histidine auxotrophic strains of
S.  typhimurium at test doses of up to 1500 g/plate, both in
the  presence and in the absence of a metabolic activation
system (Table 4). It should be noted that with Sample D
in  Trial 2 (see Study 8), when tested in the absence of the
metabolic activation system, a non-dose-responsive ﬁve-
fold  increase in mean revertant colonies was observed with
S.  typhimurium TA1537 at 1000 g/plate when compared
to  Trial 1. This could be due to the fact the concurrent
vehicle control value for mean revertant in Trial 2 was
2  ± 2 while the vehicle control value was higher in Trial
1,  which was reported at 5 ± 2. To clarify, a third trial with
the  TA1537 strain in the absence of the metabolic activa-
tion  system was conducted and found a lack of mutagenic
potential. In addition, these assays evaluated samples with
linear  APFO (Sample D), linear/branched APFO (Sample A),
and  linear/branched Na+PFOA (Sample E), it is reasonable
to  conclude that from these data, PFOA was not mutagenic
under the test conditions, regardless of salt form or iso-
meric  composition.
3.1.1.2. E. coli reverse mutation assay (Sample D, Study 8;
Sample  E, Study 12). No evidence for a signiﬁcant increase
in  the number revertant colonies was obtained in two  sep-
arate  assays utilizing a sensitive tryptophan auxotrophic
strains of E. coli at test doses of up to 1500 g/plate, both
in  the presence and in the absence of a metabolic acti-
vation system (Table 4). Similar to above, the samples
tested included both linear APFO (Sample D, tested up to
1500  g/plate) and linear/branched Na+PFOA (Sample E,
tested  up to 100 g/plate). Again, from these data, PFOA
was  not mutagenic under the test conditions regardless of
salt  form or isomeric composition.3.1.2.  Eukaryotic assay systems
3.1.2.1. S. cerevisiae D4 mitotic recombination (gene con-
version) assay (Sample A, Study 1). In the D4 strain of S.eports 1 (2014) 252–270
cerevisiae, no increase in convertant colonies were seen
with  APFO when tested in the absence or presence of a
metabolic activation at concentrations up to 500 g/plate
(Table 4). Thus, APFO did not induce non-speciﬁc DNA dam-
age  leading to mitotic recombination measured as gene
conversion in this assay.
3.1.2.2.  CHO/HGPRT forward mutation assay (Sample C,
Study  5). On the basis of a preliminary range ﬁnding
assay, dose levels of APFO at 9.75 g/mL, 19.5 g/mL, and
39  g/mL were selected for this assay. While exposure to
the  test article at these concentrations did not affect the
growth  with the regular culture medium, they did result
in  cytotoxicity with 50% cell survival in selective medium
with  6-thioguanine (Table 5). None of the three selected
dose levels showed a statistically signiﬁcant increase in
the  number of mutant frequencies. Positive controls for
non-activation (EMS) or activation (DMBA) showed the
expected signiﬁcant increased frequency in the number of
mutant  colonies proving the sensitivity of the test system.
Under these experimental conditions, APFO is considered
non-mutagenic in this forward mutation assay in CHO cells.
3.2.  Assays to assess potential for cytogenetic damage
3.2.1. In vitro chromosomal aberration studies
3.2.1.1. Chromosomal aberrations in Chinese hamster ovary
(CHO)  cells (Sample C, Study 4; Sample D, Study 7; Sample
E,  Study 11). Table 3 summarizes the results of the three
in  vitro chromosomal aberration assays conducted in CHO
cells:  one with linear/branched APFO (Sample C, Study 4);
one  with linear APFO (Sample D, Study 7); and one with
linear/branched Na+PFOA (Sample E, Study 11).
In  cultures with APFO exposure (Samples C and D)
that lacked the metabolic activation system, no signif-
icant increases in cells with chromosomal aberrations,
polyploidy, or endoreduplication were observed at APFO
concentrations up to the maximum for which data could
be  reasonably assessed, 300 g/mL. Cytotoxicity, based on
reduced  mitotic index, was evident at concentrations ran-
ging  from 100 to 300 g/mL, dependent on assay trial.
For  Na+PFOA (Sample E), ﬁve assays were conducted in
the  absence of the metabolic activation system for expo-
sure  periods of 3–41.8 h, and harvest times of 20–44.1 h.
Maximum concentrations for which data could be analyzed
varied  from 198 g/mL (41.8-h exposure, 44.1 h harvest) to
748  g/mL (3-h exposure, 44 h harvest). No chromosomal
aberrations were noted for cultures that could reasonably
be  assessed in the absence of signiﬁcant cytotoxicity. In
the  assay that incorporated a 3-h exposure period and
44  h harvest, one of the two duplicate cultures at the cyto-
toxic  748 g/mL concentration was  observed to have 11%
of  cells with aberrations, while the parallel duplicate had
4%  of cells with aberrations (a value similar to the neg-
ative and solvent control values) yielding an average of
7.5%  of metaphase cells with aberrations. These cultures
also  had 24.5% of polyploid metaphase cells. Evidence for
cytotoxicity at the 748 g/mL concentration in these cul-
tures  included a 50% reduction in monolayer conﬂuency
and a 57% reduction in mitotic index. In the assay incor-
porating a 3 h exposure and 20 h harvest, it should be
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Table 4
Salmonella typhimurium, Escherichia coli, Saccharomyces cerevisiae mutation data summary (Studies 1, 8 and 12).
S. typhimurium (mean revertants ± SD when applicable) S. cerevisiae (mean
convertants)
E.  coli (mean
revertants ± SD)
(g/plate) TA98 TA100 TA1535 TA1537 TA1538 D4 WP2uvrA
Without S9 activation
Study  1
Controls
Vehiclea 45 180 12 10 19 87 –b
Positivec 1198 1258 410 524 1555 840 –
APFO  (Sample A)
0.1  54 183 19 12 23 50 –
1  36 171 18 11 19 83 –
10  43 193 18 5 29 80 –
100  32 143 17 13 28 86 –
500  39 211 13 6 23 86 –
Study 8 (Trial 1)
Controls
Vehiclea 12 ± 0 83  ± 9 10 ± 4 5 ± 2 – – 13 ± 3
Positivec 97 ± 10 450 ± 27 429 ± 30 1087 ± 159 – – 107 ± 25
APFO (Sample D)
30  12 ± 2 89 ± 13 8 ± 3 5 ± 3 – – 9 ± 3
100 9 ± 5 94 ± 8 9 ± 4 6 ± 0 – – 12 ± 1
300 13 ± 3 96 ± 3 9 ± 2 6 ± 1 – – 10 ± 2
1000 9 ± 7 92 ± 17 9 ± 3 3 ± 2 – – 10 ± 2
1500 12 ± 1 106 ± 2 14 ± 2 6 ± 3 – – 12 ± 2
Study 8 (Trial 2)
Controls
Vehiclea 15 ± 3 79 ± 10 15 ± 5 2 ± 2 – – 17 ± 5
Positivec 196 ± 21 380 ± 28 642 ± 22 467 ± 8 – – 185 ± 24
APFO (Sample D)
30  17 ± 1 84 ± 18 17 ± 1 5 ± 1 – – 12 ± 3
100 15 ± 7 79 ± 9 10 ± 3 7 ± 10 – – 16 ± 2
300 12 ± 7 78  ± 9 9 ± 1 5 ± 3 – – 13 ± 7
1000 16 ± 5 77 ± 2 13 ± 3 10 ± 7 – – 9 ± 4
1500 15 ± 4 85 ± 12 15 ± 2 5 ± 4 – – 12 ± 4
Study 8 (Trial 3)
Controls
Vehiclea – – – 7 ± 4 – – –
Positivec – – – 84 ± 38 – – –
APFO  (Sample D)
30  – – – 7 ± 2 – – –
100  – – – 6 ± 3 – – –
300  – – – 6 ± 2 – – –
1000  – – – 6 ± 2 – – –
1500  – – – 4 ± 4 – – –
Study 12
Control
Vehiclea 13 ± 1 87 ± 2 6 ± 1 5 ± 4 – – 14 ± 4
Positivec 146 ± 15 840 ± 22 579 ± 22 215 ± 11 – – 53 ± 20
Na+PFOA (Sample E)
20 16 ± 5 97 ± 10 6 ± 2 6 ± 2 – – 17 ± 8
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Table 4 (Continued)
S. typhimurium (mean revertants ± SD when applicable) S. cerevisiae (mean
convertants)
E.  coli (mean
revertants ± SD)
(g/plate) TA98 TA100 TA1535 TA1537 TA1538 D4 WP2uvrA
67 16 ± 5 103 ± 4 15 ± 3 10 ± 3 – – 17 ± 2
200  15 ± 4 97 ± 7 11 ± 5 6 ± 3 – – 23 ± 5
670  14 ± 3 92 ± 9 7 ± 2 5 ± 1 – – 17 ± 7
1000  15 ± 6 84 ± 11 11 ± 4 9 ± 3 – – 14 ± 4
With S9 activation
Study  1
Controls
Vehiclea 46 277 20 23 24 138 –
Positivec 872 1426 262 233 963 189 –
APFO  (Sample A)
0.1  38 234 29 6 23 173 –
1  36 232 24 11 29 128 –
10  34 247 13 16 24 170 –
100  39 231 19 21 28 134 –
500  30 276 19 9 29 150 –
Study 8 (Trial 1)
Controls
Vehiclea 20 ± 6 109 ± 8 14 ± 4 8 ± 3 – – 13 ± 2
Positivec 894 ± 66 879 ± 64 133 ± 9 211 ± 26 – – 288 ± 23
APFO  (Sample D)
30  23 ± 6 99 ± 12 12 ± 2 9 ± 3 – – 13 ± 5
100  23 ± 6 100 ± 4 11 ± 4 4 ± 2 – – 18 ± 8
300  24 ± 7 102 ± 3 12 ± 3 8 ± 4 – – 14 ± 0
1000  20 ± 4 116 ± 8 14 ± 4 10 ± 2 – – 12 ± 4
1500  24 ± 1 108 ± 9 11 ± 1 6 ± 1 – – 10 ± 5
Study 8 (Trial 2)
Controls
Vehiclea 23 ± 4 91 ± 14 16 ± 2 6 ± 2 – – 15 ± 3
Positivec 736 ± 100 1041 ± 82 160 ± 32 103 ± 23 – – 116 ± 31
APFO  (Sample D)
30  23 ± 4 94 ± 5 9 ± 2 9 ± 4 – – 13 ± 3
100  28 ± 4 94 ± 16 14 ± 4 11 ± 7 – – 11 ± 5
300  29 ± 4 103 ± 15 10 ± 2 8 ± 2 – – 17 ± 6
1000  27 ± 3 105 ± 9 13 ± 3 5 ± 2 – – 18 ± 6
1500  28 ± 5 94 ± 11 10 ± 6 8 ± 1 – – 18 ± 4
Study 12
Controls
Vehiclea 20 ± 8 117 ± 2 12 ± 4 9 ± 2 – – 19 ± 1
Positivec 884 ± 98 923 ± 32 113 ± 8 112 ± 8 – – 178 ± 20
Na+PFOA (Sample E)
20 35 ± 4 112 ± 3 13 ± 3 9 ± 3 – – 20 ± 9
67  28 ± 2 118 ± 4 11 ± 3 7 ± 3 – – 17 ± 3
200  30 ± 4 114 ± 4 13 ± 4 7 ± 4 – – 13 ± 1
670  34 ± 4 123 ± 5 13 ± 2 9 ± 3 – – 16 ± 1
1000  20 ± 3 118 ± 9 12 ± 3 8 ± 2 – – 24 ± 5
a Vehicle control = 50 L deionized water.
b Not evaluated.
c See Table 2 for the corresponding positive controls for each strain.
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Table 5
CHO/HGPRT forward mutation assay (Study 5).
Dose Growth in regular
phenotypic medium, %
survival  (mean
colonies)
Growth in selective medium
with  6-thioguanine, % survival
(mean  colonies)
HGPRT mutagenesis in
selective  medium with
6-thioguanine,  mutants/106
surviving cells
Without S9 activation
APFO  (Sample C)
0  (media) 79 (157) 49 (98) 0.82
9.75 g/mL 102 (204) 49 (99) 0.81
19.5 g/mL 99 (197) 51 (102) 0.98
39 g/mL 105 (209) 43 (87) 1.16
EMS  (positive control) 10 (19) 6 (11) 503.28
With S9 activation
APFO (Sample C)
0  (media) 110 (220) 51 (102) 0.78
9.75 g/mL 118 (236) 49 (98) 0.82
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highest  concentrations of Na+PFOA (Sample E) was  con-19.5 g/mL 104 (208)
39 g/mL 94 (188) 
DMBA (positive control) 45 (90) 
oted that the combined duplicate cultures exposed to
he  748 g/mL concentration had only 38 metaphase cells
vailable for analysis as opposed to the 200 required by
rotocol. Although seven metaphase cells were observed
o  have chromosomal aberrations, the 748 g/mL cultures
ere excluded from analysis due to severe toxicity, and
he  chromosomal aberrations were attributed to the obvi-
us  high toxicity at 748 g/mL. No increase in polyploid
ells was evident in the assays conducted in the absence
f  metabolic activation, with the exception of one of the
wo  duplicate cultures at 748 g/mL. Therefore, Na+PFOA
as  not considered clastogenic in the absence of severe
ytotoxicity.
When tested in the presence of the metabolic activa-
ion system, no increase in chromosomal aberration was
bserved after linear/branched APFO exposure (Sample C)
t  concentrations up to the maximum concentration for
hich  data could be assessed, 750 g/mL. Similarly, 3-h
xposure to linear APFO (Sample D) in the presence of
he  metabolic activation system with a 20 h harvest time
id  not produce cytogenetic effects in the initial trial at
oncentrations up to the maximum analyzed, 750 g/mL.
owever, increases over control in percent cells with aber-
ations  were observed in two conﬁrmatory trials with
ample D (3-h exposures and 20.1 h and 44.2 h harvest
imes) at the highest concentrations for which data could
e  assessed in each trial (12.5% and 13% at 750 g/mL and
25  g/mL, respectively, for the 20.1 h and 44.2 h assays,
espectively). These ﬁndings were accompanied by cyto-
oxicity  as evidenced by an increase in the percent of cells
ith  endoreduplication at 675 g/mL and higher concen-
rations and effects on monolayer conﬂuence and mitotic
ndex.  In the 20.1 h assay, for the 600, 675, and 750 g/mL
oncentrations, monolayer conﬂuence was reduced by 15,
0,  and 45%, respectively, and mitotic index by 15, 11,
nd  30%, respectively. Similarly, in the 44.2 h assay, for the
75,  750, and 825 g/mL concentrations, monolayer con-
uence  was reduced 15, 45, and 55%, respectively, with
itotic index reductions of 17, 56, and 53%, respectively.
loating dead cells and debris were also noted at 750 and
25  g/mL.47 (94) 1.06
40 (80) 2.00
5 (10) 566.90
When  Na+PFOA was  tested in the presence of the
metabolic activation system in three assay trials, no
increase in chromosomal aberrations or polyploid cells
was  noted at concentrations up to 500 g/mL; however,
contradictory results were observed at 748 g/mL in two
replicate assay trials in which cells were exposed 3 h with
a  20 h harvest time. At that concentration, a statistically
signiﬁcant percent of cells with chromosomal aberra-
tions (14.5%) and percent polyploid cells (7%) occurred
in  one of the two replicate assay trials but not in the
other. The highest concentration tested in these two repli-
cate  assay trials, 1000 g/mL, was  clearly cytotoxic, and
increased percent cells with aberrations (31.5% and 42.7%)
and  increased percent polyploid cells (15% and 26%) were
statistically signiﬁcant over control in both replicate assay
trials  at this concentration. Cytotoxicity at 1000 g/mL was
severe,  consisting of large reductions in monolayer con-
ﬂuency  (70% and 95%) and mitotic index (14% and 47%).
In  the single assay trial with 3-h exposure period and
44.1  h harvest time, no increase in the percent of cells
with either chromosomal aberrations or polyploidy was
observed at 748 g/mL, the highest concentration that
allowed for analysis. At the highest concentration tested
under these exposure and harvest conditions, 1000 g/mL,
mitotic  index at was reduced by 70%, disallowing analysis.
The  observation of an increase in chromosomal aber-
ration and polyploidy with Sample D at cytotoxic
concentrations in the presence of a metabolic activation
system are of questionable relevance for the assessment of
the  clastogenicity of APFO. These effects were not noted
in  the absence of the metabolic activation system or in
the  absence of cytotoxicity. The physical/chemical prop-
erties  of APFO preclude metabolic activation, DNA binding,
and  intercalation. Therefore, APFO was  not considered to
be  a selective genotoxic agent either in the presence or in
the  absence of a metabolic activation system. Similarly, the
observed  chromosomal aberrations and polyploidy at thesidered to be the likely consequence of severe cytotoxicity
leading to disruption of normal cellular processes and not
a  speciﬁc genotoxic effect of PFOA [23,24].
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Table 6
Chromosomal aberrations assay summary data with human whole blood lymphocytes (Study 10).
22.0–22.1 h 46.0  h
#Cela #Abb %Celc %>1d %Polye % Endf %Mitg #Cela #Abb %Celc %>1d %Polye % Endf %Mitg
Without S9 activation
Controls
Media  200 0.01 0.5 0 0 0 2.9
200  0 0 0 0 0 4.3 200 0.03 2 0.5 0 0 4.9
Water  200 0 0 0 0 0 4.0
200  0.01 1 0 0 0 4.2 200 0.02 0 0 0 0 5.4
MMCh 50 0.40 38.0* 2.0* 0 0 2.8
50  0.48 36.0* 12.0* 0 0 1.7
[Na+PFOA], g/mL (Sample E)
12.4 0i –j – – – – 5.6
25  200 0 0 0 0 0 4.1 200 0.01 0.5 0 0 0 6.2
25.4  0i – – – – – 2.5
50 200 0.01 0.5 0 0 0 4.2 200 0 0 0 0 0 6.3
50.6  200 0.01 0.5 0 0 0 3.3
100 200 0 0 0 0 0 3.6 200 0.01 1 0 0 0 5.8
101  200 0.01 0.5 0 0 0 3.3
112 200 0.01 0.5 0 0 0 1.5 200 0.01 0.5 0 0 0 2.2
202  200 0.02 1.5 0.5 0 0 2.0
240 0k – – – – – 1.1 0k – – – – – 0.4
302  200 0.02 2.0 0 0 0 1.8
320 0k – – – – – 0.3 0k – – – – – 0.1
400  0k – – – – – 0.3 0k – – – – – 0.1
402  0k – – – – – 0.2
With S9 activation
Controls
Media  200 0 0 0 0 0 4.9
200  0.01 0.5 0 0 0 4.6 200 0.01 0.5 0 0.5 0 8.1
Water  200 0.01 1 0 0 0 6.0
200  0.02 1.5 0 0 0 3.9 200 0.01 1 0 0 0 6.6
CPl 50 0.7 48.0* 18.0 0 0 1.5
50  0.38 34.0* 4 0 0 0.5
[Na+PFOA], g/mL (Sample E)
50 200 0 0 0 0 0 4.3 0i – – – – – 7.7
50.6  0i – – – – – 5.1
100 200 0.02 1.5 0 0.5 0 3.3 200 0 0 0 0.5 0 8.0
101  200 0 0 0 0 0 4.8
200 200 0.01 1 0 0 0 3.7 200 0.01 0.5 0 0.5 0 7.1
202  200 0 0 0 0 0 5.1
300 200 0.04 3.0 0.5 0.5 0 1.2 200 0.01 0.5 0 1.0 0.5 5.6
302  200 0.02 1.5 0.5 1  0 3.4
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3.2.1.2. Chromosomal aberrations in human whole blood
lymphocytes (Sample E, Study 10). Presented in Table 6
are  data from the chromosomal aberration assay using
human whole blood lymphocytes. The test compound
produced cytotoxicity at concentrations above 100 g/mL
in  the absence of the metabolic activation system and
above 200 g/mL with the metabolic activation system.
Regardless of S9 activation, Na+PFOA treatments caused
a  dose-dependent reduction in mitotic index indicative of
toxicity.  The extent of % reduction was very pronounced at
higher  Na+PFOA doses. Even so, when chromosomal aber-
rations  were analyzed from cultures treated with higher
concentrations of Na+PFOA doses, there were no statis-
tically signiﬁcant increases in the percent of cells with
chromosomal aberrations or polyploidy, when compared
to  the cells treated with vehicle control. Endoreduplica-
tions were generally not observed following treatment
with Na+PFOA with the exception of one instance at
highly toxic dose level at which the mitotic index was
reduced by about 80%. This effect was considered to be
the  consequence of generalized cell damage as opposed
to  selective genotoxicity, because it occurred at dose lev-
els  for which it was not possible to assess a sufﬁcient
number of surviving metaphase cells in one of the dupli-
cate  cell cultures. Cells treated with positive controls
had statistically signiﬁcant increases in the percent cells
with  aberrations in the absence or presence of metabolic
activation.
3.2.2. In vivo mouse micronucleus assay (Sample C,
Study 3; Sample D, Study 6; Sample E, Study 9)
Presented in Table 7 are data for percent micronucleated
PCEs and the ratio between PCE and NCE from three sep-
arate  studies, one with Na+PFOA (Sample E, Study 9) and
two  with APFO (Sample C, Study 3 and Sample D, Study 6).
No  signiﬁcant increases in bone marrow PCE micronuclei
occurred in mice treated with the test compounds in any
of  the three studies. On one occasion, in females treated
with 800 mg/kg APFO at the harvest time 48 h post dosing,
the  rate of micronucleated PCE was slightly increased over
vehicle  control (0.3%). This singular observation is consid-
ered  not biologically relevant because: (1) it was  within the
historical  control range, (2) it was  not observed at a later
harvest time (72 h post dose) in the same experiment, (3)
it  was restricted to one sex, and (4) it was not observed at
an  even higher dose in females treated with 1000 mg/kg of
Na+PFOA.
In  mice treated with cyclophosphamide, the positive
control, both sexes had a statistically signiﬁcantly increase
in  the percentage of micronucleated cells. Male and female
mice  dosed with 1000 mg/kg of Na+PFOA had a statistically
signiﬁcant decrease in PCE/NCE ratio, indicating bone mar-
row  toxicity and demonstrating that the test compound
had reached the target organ.
3.3. Cell transformation (Sample B, Study 2)The data for the C3H 10T1/2 cell transformation
assay are presented in Table 8. While APFO showed a
dose-dependent decrease in colony formation and plat-
ing  efﬁciency, there was  no morphologic evidence of
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Table  7
In  vivo mouse micronucleus data summary table, data are presented as mean ± standard error. Adult male and female Crl:CD-1® (ICR) BR mice were treated
with  a single oral dose of test compound with n = 5/sex/time point unless speciﬁed otherwise (Studies 3, 6, and 9).
Compound Dose (mg/kg) Time % Micronucleated PCEs (meana ± SE) Ratio PCE:NCE (mean ± SE)
Male Female Male Female
Na+PFOA 0 (vehicle control) 24 h PDb 0.14 ± 0.02 0.02 ± 0.02 0.51 ± 0.06 0.69 ± 0.11
(Sample  E) 250 24 h PD 0.28 ± 0.05 0.00 ± 0.00 0.69 ± 0.09 0.75 ± 0.17
(Study  9) 48 h PD 0.00 ± 0.00 0.02 ± 0.02 0.68 ± 0.08 0.74 ± 0.06
72  h PD 0.06 ± 0.02 0.02 ± 0.02 0.36 ± 0.08 0.59 ± 0.06
500  24 h PD 0.12 ± 0.04 0.04 ± 0.02 0.69 ± 0.07 0.64 ± 0.05
48  h PD 0.02 ± 0.02 0.02 ± 0.02 0.79 ± 0.07 0.65 ± 0.01
72  h PD 0.20 ± 0.07 0.06 ± 0.04 0.47 ± 0.07 0.64 ± 0.07
1000  24 h PD 0.06 ± 0.04 0.10 ± 0.04 0.80 ± 0.08 0.79 ± 0.09
48  h PD 0.15 ± 0.09c 0.06 ± 0.02 0.56 ± 0.10 0.63 ± 0.06
72  h PD 0.17 ± 0.03d 0.03 ± 0.03c 0.17 ± 0.04* 0.24 ± 0.05*
Cyclophosphamide 80 (positive control) 24 h PD 5.44 ± 0.37* 2.50 ± 0.33* 0.64 ± 0.07 0.63 ± 0.05
APFO 0 (vehicle control) 24 h PDb 0.08 ± 0.04 0.08 ± 0.04 0.64 ± 0.11 0.60 ± 0.07
(Sample  E) 200 24 h PD 0.14 ± 0.05 0.04 ± 0.02 0.59 ± 0.05 0.66 ± 0.06
(Study  3) 48 h PD 0.16 ± 0.05 0.08 ± 0.04 0.56 ± 0.08 0.52 ± 0.07
72  h PD 0.10 ± 0.05 0.02 ± 0.02 0.44 ± 0.06 0.61 ± 0.06
400  24 h PD 0.16 ± 0.05 0.06 ± 0.04 0.72 ± 0.08 0.65 ± 0.09
48  h PD 0.08 ± 0.04 0.10 ± 0.04 0.66 ± 0.13 0.53 ± 0.11
72  h PD 0.10 ± 0.03 0.26 ± 0.21 0.45 ± 0.12 0.65 ± 0.06
800  24 h PD 0.12 ± 0.06 0.04 ± 0.02 0.59 ± 0.13 0.72 ± 0.17
48  h PD 0.16 ± 0.05 0.30 ± 0.04c,* 0.49 ± 0.08 0.35 ± 0.09
72  h PD 0.08 ± 0.02 0.12 ± 0.06 0.31 ± 0.08 0.56 ± 0.20
Cyclophosphamide 80 (positive control) 24 h PD 3.06 ± 0.50* 4.24 ± 0.47* 0.63 ± 0.10 0.81 ± 0.07
APFO 0 (vehicle control) 24 h PDb 0.08 ± 0.06 0.08 ± 0.04 0.53 ± 0.08 0.73 ± 0.07
(Sample  D) 150 24 h PD 0.20 ± 0.06 0.06 ± 0.06 0.71 ± 0.08 0.92 ± 0.05
(Study  6) 48 h PD 0.02 ± 0.02 0.08 ± 0.04 0.59 ± 0.05 0.53 ± 0.04
72  h PD 0.08 ± 0.06 0.12 ± 0.07 0.52 ± 0.08 1.12 ± 0.43
300  24 h PD 0.12 ± 0.06 0.18 ± 0.06 0.69 ± 0.12 1.03 ± 0.13
48  h PD 0.12 ± 0.04 0.06 ± 0.04 0.63 ± 0.03 0.54 ± 0.06
72  h PD 0.10 ± 0.08 0.10 ± 0.06 0.45 ± 0.08 0.85 ± 0.21
600  24 h PD 0.30 ± 0.13 0.08 ± 0.06 0.69 ± 0.07 0.75 ± 0.07
48  h PD 0.00 ± 0.00 0.04 ± 0.02 0.60 ± 0.06 0.56 ± 0.07
72  h PD 0.08 ± 0.06 0.12 ± 0.04 0.49 ± 0.11 0.78 ± 0.21
Cyclophosphamide 80 (positive control) 24 h PD 3.86 ± 0.55* 3.58 ± 0.79* 0.61 ± 0.05 0.96 ± 0.17
a Mean of 1000 micronucleated PCEs per mouse.
b PD = post dose.
c Mortality occurred during exposure in one of the ﬁve mice.
d Mortality occurred during exposure in two of the ﬁve mice.
* Statistically signiﬁcantly different than vehicle control, p < 0.05.
transformation in the colonies treated with APFO. A longer
term  foci transformation regimen was also evaluated for
APFO  and there was no evidence of foci or transformed
foci. The response to positive controls (benzo(a)pyrene and
butadiene  epoxide) conﬁrmed the sensitivity of the assay
as  expected, and all ﬁndings observed in positive controls
were  absent in solvent controls. In summary, APFO did not
induce  cell transformation in this in vitro system.
4. Discussion
The potential genotoxicity of PFOA was tested in ﬁfteen
assays covering several genotoxicological endpoints. These
assays  included: seven mutation assays (three in vitro
reverse mutation assays with histidine auxotrophic strains
of  S. typhimurium, two in vitro reverse mutation assays
with the tryptophan auxotrophic E. coli WP2uvr  strain,
one  in vitro mitotic recombination (gene conversion) assay
with  S. cerevisiae D4, and an in vitro Chinese hamster ovary(CHO)/HGPRT forward mutation assay); seven cytogenetic
aberration studies (three in vitro Chinese Hamster Ovary
chromosomal aberration studies, an in vitro human whole
blood  lymphocyte chromosomal aberration study, and
three  in vivo mouse micronucleus assays); and an in vitro
C3H  10T1/2 cell transformation assay. Although these stud-
ies  have been available as laboratory reports via the United
States  Environmental Protection Agency Administrative
Record 226 (AR-226, see Table 1) and brieﬂy summarized
in previous reviews [5,6], the details of these assays have
not  been published. The results of these assays demonstrate
no  signiﬁcant potential for genotoxicity, regardless of PFOA
salt  form (ammonium or sodium) or isomeric composition
(combination of linear and branched or pure linear).
Many of the assays reported incorporated a metabolic
activation system. It should be noted that metabolism of
PFOA  by microsomal systems has never been demonstrated
and would not be expected based on the exceptional
strength of the carbon-ﬂuorine bonds in the alkyl chain
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Table 8
Cell  transformation assay using C3H 10T1/2 cells (Study 2).
Colony transformation potential determination (24 h compound exposure followed by additional 14 days of culturing)
Compound Dose (g/mL) Mean # of colony Mean plating efﬁciency Combined type II and type III colonies
Transformed
colonies/cell
Transformed
colonies (%)
Controls
0  (solvent control) 43 93.65 0 0
0  (serum baseline control) 45.8 100 0 0
Benzo(a)pyrene
0.1  44.33 96.79 4.43 × 10−3 3.0
1.0  40.5 88.41 7.2 × 10−3 5.33
2.5  37.83 82.51 7.7 × 10−3 6.16
5  29.3 63.52 8.86 × 10−3 9.08
10  26.0 56.78 11.1 × 10−3 12.81
Controls
0  (solvent control) 41.33 96.9 0 0
0  (serum baseline control) 43.0 100 0 0
APFO (Sample B)
1 41.0 95.39 0 0
2.5  40.5 94.21 0 0
5  38.67 89.95 0  0
10  37.5 87.23 0 0
20  37.5 87.23 0 0
50  35.0 81.44 0 0
100  32.67 79.99 0 0
200  27.61 63.15 0 0
Foci transformation potential determination (continuous compound exposure in culture)
Compound Dose (g/mL) Days in culture Combined type II and type III foci % transformation per cell
per  plate (based on 300
cells/plate)
Total # of foci # of plates Average # of
foci  per plate
Butadiene 0.0001 36 64 3 21.3 7.1
Diepoxide 0.005 36 84 3 28.0 9.33
0.001 36 129 3 43.0 14.33
Controls
0 (solvent control) 38 0 6 0 0
0 (serum baseline control) 38 0 6 0 0
0 
0 
0 
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25–29]. Therefore, formation of an active metabolite by
xposure of PFOA to the microsomal activation system is
recluded.  However, it is worth noting that the S9 proteins
ncluded in the metabolic activation system may  sequester
FOA  through ionic binding [30].
PFOA has not shown the potential to induce DNA
oint mutations or mitotic recombinations in a series of
ssay  systems. These included the bacterial reverse muta-
ion  assays utilizing S. typhimurium histidine auxotrophic
trains (TA98, TA100, TA1535, TA1537, and TA1538) and
.  coli tryptophan auxotroph (WP2uvr), the S. cerevisiae D4
itotic  gene conversion/recombination assay, and the Chi-
ese  hamster ovary cell (CHO) forward mutation assay.
hree independently published studies utilizing various S.
yphimurium  strains exposed to PFOA in the presence or
bsence  of a metabolic activation system were consistent6 0 0
6 0 0
6 0 0
with  the results reported herein. In one published study,
PFOA  was  not mutagenic in four strains of S. typhimurium
(TA98, TA100, TA102, TA104) when tested at concentra-
tions up to 500 M (206 g/mL) [31]. In another study
by Endo et al. [32], S. typhimurium strains TA 98 and
TA100 exposed to PFOA at unspeciﬁed concentrations did
not  show an increase in revertant colonies. Using the
assay for umuC gene expression assay with S. typhimurium
TA1535/pSK1002 (hisG46, rfa, uvrB) to analyze for -
galactosidase activity, no signiﬁcant increased activity was
seen  at concentrations of PFOA up to 1000 M (413 g/mL),
indicating a lack of mutagenicity in the assay system
[33].
The studies reported herein also demonstrated
that PFOA lacked the potential to produce cytogenetic
changes, including chromosomal damage, aberrations and
ology R268 J.L. Butenhoff et al. / Toxic
polyploidy under non-cytotoxic exposure conditions.
These studies included in vitro assays to assess the poten-
tial  of PFOA to produce chromosomal aberrations in
cultured human lymphocytes and CHO cells, as well as the
in  vivo assessment of micronucleated polychromatic eryth-
rocytes  in PFOA-treated mice. In CHO cells, aberrations
were observed only in the presence of signiﬁcant cytotox-
icity  in three of 16 assay trials that were conducted. PFOA
does  not possess the chemical/physical characteristics of
a  genotoxic agent, is incapable of metabolism [25–29], is
not  expected, based on its structure, to bind covalently to
DNA  or to intercalate into the double helix, and lacks the
planar  characteristics of an intercalating agent. Therefore,
it  is reasonable to assume that the positive ﬁndings at high
and  cytotoxic concentrations in some CHO chromosomal
aberration assay trials were the consequence of cytotoxic
disruption of normal cellular processes and not a speciﬁc
genotoxic effect. This is supported by the general lack
of  genotoxicity in the in vitro chromosomal aberration
study in human lymphocytes, in which no evidence of
an  increase in chromosomal aberrations, polyploidy, or
endoreduplication was observed. Previously published
reports in which HepG2 cells were exposed in vitro to
PFOA  have provided mixed results with respect to the
production of DNA strand breaks and micronuclei [34–36].
Florentin et al. [35] observed no increases in HepG2 cell
DNA  strand breaks or micronuclei at PFOA concentrations
up to 800 M (330 g/mL), and Eriksen et al. [34] also
found no increase in PFOA-induced DNA strand breaks in
this  cell line at concentrations up to 400 M (165 g/mL).
By  contrast, Yao and Zhong [36] observed increases in
micronuclei in HepG2 cells exposed to 100–400 M
(41–165 g/mL) PFOA and increases in DNA strand
breaks at concentrations of 50–400 M (21–165 g/mL).
Among the assays reported here, the lack of increases
in mouse bone marrow micronucleated polychromatic
erythrocytes found in the three separate in vivo mouse
micronucleus assays with respective oral doses of 600, 800,
and  1000 mg/kg provides compelling evidence for a lack of
potential  for PFOA to induce cytogenetic alteration. Taken
together, these assays demonstrate a lack of potential for
chromosomal effects as a result of PFOA exposure.
Using the C3H 10T1/2 cell culture system in vitro, APFO
did  not produce cell transformation at concentrations up
to  the maximum tested, 200 g/mL. Cell transformation,
whether mutational or epigenetic, alters the normal prop-
erties,  organization, and propagation of cells in culture with
emphasis  on the acquisition of properties typical of cancer
cells.  One additional report [37], published previously, has
examined  to potential of PFOA to produce cell transforma-
tion in Syrian hamster embryo (SHE) cells. PFOA tested up
to  300 M (124 g/mL) did not induce SHE cell transfor-
mation frequency. No genotoxicity in SHE cells was seen
via  the COMET assay, nor was DNA breakage increased in
benzo--pyrene initiated cells. The data reported herein
and  that reported by Jacquet et al. [38] demonstrate a lack of
cell  transformation potential in vitro to be associated with
PFOA.
The  data reported herein are designed to observe
for genotoxic effects under non-cytotoxic exposure con-
ditions  to PFOA; however, there are several publishedeports 1 (2014) 252–270
articles that have reported cytotoxic disruption of cellu-
lar  homeostasis, modiﬁed gene expression, and increased
intracellular ROS production as a consequence of in vitro
exposure to PFOA. The potential for PFOA to induce oxida-
tive  stress, which may  relate to potential cytotoxicity
and genetic alteration, has been investigated in several
in  vitro studies and at least one in vivo study. Freire
et al. [31] reported an increase in PFOA-induced reac-
tive  oxidative species (ROS), as measured by oxidation
of 2′,7′-dichloroﬂuorescein diacetate (DCFH-DA) to 2′,7′-
dichloroﬂuorescein (DCF) in the monkey kidney-derived
Vero cell line at the highest concentration tested 500 M
(210  g/mL); however, cytotoxicity in these cells was  evi-
dent  at concentrations greater than 50 M (21 g/mL) with
dose-related mitochondrial changes as ﬁssion and reduced
cell  density and increased apoptosis. Using HepG2 cells
exposed to PFOA, Yao and Zhong [36] reported an observed
increase in ROS (measured as DCF ﬂuorescence) as well as
8-hydroxydeoxyguanosine (8-OHdG) DNA adducts. They
reported  micronuclei breaks occurred with PFOA concen-
trations at 100–400 M (42–168 g/mL) and DNA strand
breaks at 50–400 M (21–168 g/mL). Also using HepG2
cells, Hu and Hu [39] found that PFOA concentrations
from 50 to 200 M (20–82 g/mL) induced production
of ROS, dissipation of mitochondria membrane potential,
and  apoptosis. Cellular antioxidant defenses were reduced,
including glutathione content, as well as activities of cata-
lase,  superoxide dismutase, and glutathione reductase.
Differential expression of genes such as p53, Bcl-2, caspase-
9  was evident. The authors suggested that these effects
occurred via a mechanism in which the homeostasis of
antioxidant systems was overwhelmed, thus modifying
expression of genes involved with the apoptotic regulation.
In  another experiment with HepG2 cells, Eriksen et al. [34]
found  that PFOA increased the intracellular ROS production
by  1.52 fold in a non-concentration-dependent manner and
did  not cause DNA strand breakage and acid-labile sites or
an  increase in formamidopyrimidine-DNA-glycolase sites;
thus,  the authors concluded that PFOA, along with other
perﬂuorinated chemicals, induced only modest effects in
terms  of ROS production and produced no DNA damage
in  HepG2 cells. Florentin et al. [35] also exposed HepG2
cells to PFOA for 24 h and observed cytotoxicity at con-
centrations of 200–800 M (83–330 g/mL); however, no
increases in ROS, DNA strand breaks, or micronuclei were
observed. Following a single intraperitoneal injection of
100  mg/kg PFOA, Takagi et al. [40] found increased liver
weights and increased liver 8-OHdG adducts of male Fisher
344  rats. It should be noted that the level of 8-OHdG
adducts reported was  a marker for oxidative DNA damage
only  and not a measurement of PFOA–DNA adduct.
Because PFOA is a strong organic acid with excellent sur-
factant  and surface tension-lowering properties, it is likely
that  some of the biochemical changes observed in vitro,
as  reported by others above, were mediated by cytotox-
icity and surfactant-induced membrane disruption. For
perspective on cytotoxicity of PFOA, PFOA has been shown
to  be similar to naturally occurring fatty acids as well
as  other perﬂuorinated carboxylates with respect to hav-
ing  low cytotoxicity in human colon carcinoma (HCT116)
cells. For PFOA, the 24-h EC50 and 72-h EC50 were 937 M
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387 g/mL) and 313 M (130 g/mL), respectively, while
he  72-h EC50’s for the naturally occurring fatty acids
ecanoic, dodecanoic, and octadecanoic acids ranged
rom 677 M (279 g/mL) to 2907 M (1200 g/mL) [41].
herefore, these inconclusive observations are difﬁcult to
ranslate  to in vivo conditions and they do not contradict
he conclusion that PFOA has not shown the potential for
enotoxicity under non-cytotoxic conditions.
When considering the structural and chemical charac-
eristics of PFOA relative to what is known about direct
utagens and clastogens, it is evident that PFOA does not
ossess  structural or chemical properties that would be
onsistent with those known to be important in identify-
ng  potential genotoxic agents. The complete ﬂuorination
f  the seven carbons of the chain that supports the carboxyl
roup precludes chemical reactivity under physiological
onditions. Neither is PFOA a planar molecule capable of
ntercalation into DNA. Interactions of PFOA with DNA
sing  circular dichroism indicated a change in DNA con-
ormation with the binding to DNA being non-covalent in
hich  PFOA aligned along the backbones and interacted
ith the homolateral bases via hydrophobic interactions
42]. DNA binding was not found when tested at either 50
21  g/mL) or 500 M (210 g/mL) concentrations [43]. In
ddition, no signiﬁcant oxidative DNA damage was pro-
uced  in primary rat testicular cells [44] and Ddit3 gene
xpression (marker for DNA damage) was unaltered by
FOA  in HepG2/C3A human hepatoma cells at concentra-
ions below 200 M (83 g/mL) [45].
In  vivo and in vitro mutagenicity/genotoxicity tests are
seful  predictive tools for evaluating potential genotoxic
arcinogens and mutagenicity of chemicals. The results
eported in this paper are consistent with the carcinoge-
icity data obtained from two chronic dietary studies, in
hich  daily dietary treatment with branched/linear APFO
p  to 300 ppm in the diet of Sprague Dawley rats up to
04  weeks did not produce any excess malignant (inva-
ive)  tumors of any type when compared to the control
46,47]. From a mechanistic perspective, the benign tumors
bserved in these cancer bioassays have been proposed to
e  most likely the result of non-genotoxic processes related
o  activation of the xenosensor nuclear receptors in rats
uch  as NR1C1 (PPAR) [48–51].
Therefore, with the exception of limited positive ﬁnd-
ngs  at high and cytotoxic concentrations in some CHO
hromosomal aberration assay trials which reﬂected the
ikely  consequence of cytotoxic disruption of normal cel-
ular  processes and not a speciﬁc genotoxic effect, at
on-cytotoxic conditions, the results of the studies pre-
ented  in this paper and other published results clearly
emonstrate the absence of direct mutagenic or genotoxic
isk  associated with PFOA.
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